Effectiveness and safety of a single-tablet regimen of emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in infectious diseases department

被引：0
|
作者：
Xerinda, S. [1 ]
Neves, N. [1 ]
Santos, S. [1 ]
Pineiro, C. [1 ]
Poinhos, R. [2 ]
Soares, J. [1 ]
Serrao, R. [1 ]
Sarmento, A. [1 ]
机构：
[1] Ctr Hosp Sao Joao, Dept Infect Dis, Oporto, Portugal
[2] Univ Porto, Fac Ciencias Nutr & Alimentacao, P-4100 Oporto, Portugal
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18383
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：168 / 169
页数：2
相关论文
共 50 条
  • [41] THE 48-WEEK EFFICACY AND SAFETY OF SWITCHING TO FIXED-DOSE EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF IN HIV-1-INFECTED PATIENTS RECEIVING HAART
    Carlevari, M.
    DeJesus, E.
    Pozniak, A.
    Gallant, J.
    Arribas, J.
    Lazzarin, A.
    Zhou, Y.
    Cheng, A.
    Warren, D.
    Enejosa, J.
    INFECTION, 2009, 37 : 62 - 62
  • [42] Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
    Orkin, C.
    Eron, J.
    Rockstroh, J.
    Podzamczer, D.
    Esser, S.
    Vandekerckhove, L.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [43] Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients
    Rodriguez-Gonzalez, Carmen Guadalupe
    Chamorro-de-Vega, Esther
    Ortega-Navarro, Cristina
    Alonso, Roberto
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (07) : 633 - 643
  • [44] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [45] Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen
    Brown, Kimberley
    Thomas, David
    McKenney, Kevin
    Reeder, Michael
    Simonson, Richard Bruce
    Bicer, Ceyhun
    Nettles, Richard E.
    Crauwels, Herta
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 541 - 548
  • [46] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Zolopa, A.
    Gallant, J.
    Cohen, C.
    Sax, P.
    Dejesus, E.
    Mills, A.
    Wohl, D.
    Liu, H.
    Rhee, M.
    Szwarcberg, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [47] STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA ≤ 100,000 copies/mL through week 96
    Wilkins, E.
    Moyle, G.
    Orkin, C.
    Fisher, M.
    Johnson, M.
    Arribas, J.
    Van Lunzen, J.
    Garner, W.
    Porter, D.
    Bosse, M.
    Scharen-Guivel, V.
    Reilly, G.
    Robinson, C.
    Smith, A.
    HIV MEDICINE, 2014, 15 : 115 - 116
  • [48] Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants
    Flynn, Patricia M.
    Mirochnick, Mark
    Shapiro, David E.
    Bardeguez, Arlene
    Rodman, John
    Robbins, Brian
    Huang, Sharon
    Fiscus, Susan A.
    Van Rompay, Koen K. A.
    Rooney, James F.
    Kearney, Brian
    Mofenson, Lynne M.
    Watts, D. Heather
    Jean-Philippe, Patrick
    Heckman, Barbara
    Thorpe, Edwin, Jr.
    Cotter, Amanda
    Purswani, Murli
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) : 5914 - 5922
  • [49] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Cohen, Calvin
    Elion, Richard
    Ruane, Peter
    Shamblaw, David
    DeJesus, Edwin
    Rashbaum, Bruce
    Chuck, Steven L.
    Yale, Kitty
    Liu, Hui C.
    Warren, David R.
    Ramanathan, Srinivasan
    Kearney, Brian P.
    AIDS, 2011, 25 (06) : F7 - F12
  • [50] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults
    Caroline M. Perry
    Drugs, 2014, 74 : 75 - 97
12345